The role of neoadjuvant androgen deprivation (NAD) in high-risk prostate cancer patients receiving high-dose radiotherapy (RT) remains unstudied. To evaluate the effect of a course of NAD, we reviewed the experiences of three institutions treating these patients with combined RT and high-dose rate brachytherapy (HDR). Of 1260 prostate cancer patients with high-risk features (pretreatment prostate-specific antigen (PSA) X10, Gleason Score (GS) X7, or T stage XT2b), 560 received no NAD (n ¼ 308) or NAD for p6 months (n ¼ 252). Median dose to the prostate from RT and HDR was 42 and 23 Gy, respectively. Average total biologic equivalent prostate dose was 4100 Gy (a/b ¼ 1.2). Median follow-up was 4.3 years. Pretreatment characteristics were similar on v 2 tables for all 560 patients treated with or without NAD including pretreatment PSA (P ¼ 0.11), GS (P ¼ 0.4), and clinical T stage (P ¼ 0.2). Outcomes worsened for patients receiving NAD (5-year distant metastasis (DM) 10 vs 5% (P ¼ 0.04); cause-specific survival (CSS), 93 vs 98% (P ¼ 0.005)).
Introduction
Several randomized trials have found a benefit to adding androgen deprivation (AD) to low-dose radiation therapy (RT) (65-70 Gy). [1] [2] [3] [4] [5] [6] [7] As several randomized trials have shown a benefit in the treatment of prostate cancer with high-dose RT, the need for AD with the use of a high-dose technique needs to be evaluated. [8] [9] [10] AD when combined with low-dose radiation has been shown to be an effective adjuvant treatment and to improve overall survival for prostate cancer patients with high-risk features. 5, 11 However, in regards to neoadjuvant androgen deprivation (NAD), a phase III randomized study from Canada has failed to show an improvement for 8 vs 3 months of hormonal ablation given before RT for clinically localized prostate cancer. 12 Therefore, the utility of the neoadjuvant may not be favored over concurrent/adjuvant AD. Given these concerns, it was felt that the effect of NAD combined with high-dose RT needed to be studied further. The ideal way to address this issue would be to conduct a well-designed randomized trial. Nevertheless, the lack of published data and the belief that hormonal therapy may halt the progression of prostate cancer has prompted the use of neoadjuvant hormonal therapy before the implementation of RT. Therefore, it was felt that an analysis of our experience in regards to this issue was well warranted.
A collaborative prostate cancer high-dose rate brachytherapy (HDR) group was established between the California Endocuritherapy Cancer Center (CET), Kiel University Hospital (KUH), and William Beaumont Hospital (WBH) to analyze the effect of HDR treatment in prostate cancer patients. In our collaborative group, all high-risk prostate cancer patients were treated with a combination of external beam RT and an HDR prostate boost.
In previous analyses of the HDR collaborative group using a smaller sample and shorter follow-up, no apparent benefit was found for the use of AD in intermediate-or high-risk patients. 13, 14 To fully evaluate the potential impact of NAD, we reviewed the outcome of patients treated with AD for p6 months compared to a similar group of patients. These patients were matched by pretreatment prostate-specific antigen (PSA), age, Gleason score (GS), and T stage for analysis.
Materials and methods
From 1986 to 2003, 1491 patients were treated at CET, KU, and WBH with external beam RT and HDR prostate brachytherapy. Patient characteristics are listed in Table  1a and 1b. One thousand two hundred-sixty patients with high-risk features, defined by a pretreatment PSAX10, GSX7, or T stageXT2b were selected. To decrease the potential impact of nonprostate cancerrelated comorbidities and their effect on recommendations for AD, patients p70 years of age were selected. Minimum follow-up for all patients was 18 months owing to the inherited inaccuracies of the ASTRO definition in cases with short follow-up because of backdating. Five hundred and sixty patients were available for analysis.
Of the 560 patients, 278 (49.6%) were treated at the CET, 94 (16.8%) at KUH, and 188 (33.6%) at WBH. All 560 patients were treated with a combination of external beam RT with two high-dose radiation prostate brachytherapy implants as a boost. Two hundred fifty-two patients underwent neoadjuvant/concurrent AD for p6 months for a median of 3 months (range, 1-6 months). Three hundred-eight had no neoadjuvant or concurrent hormonal therapy given. AD consisted of a combination of a luteinizing hormone-releasing hormone (LHRH) agonist (leuprolide acetate or goserelin) with or without nonsteroidal antiandrogen (flutamide or bicalutamide). Leuprolide was delivered intramuscularly each month at a dose of 7.5 or 22.5 mg every 3 months. Goserelin was administered subcutaneously each month at a dose of 3.6 or 10.8 mg every 3 months. Patients treated with either LHRH agonist were used for analysis since both have been shown to be equivalent for prostate cancer therapy. 15 Flutamide was taken orally at a dose of 250 mg every 8 h and starting 1-7 days before the LHRH agonist to block the transient increase in testosterone caused by the LHRH agonist. Bicalutamide taken orally at a dose of 50 mg every day starting 1-7 days before LHRH agonist was also acceptable.
The initial evaluation for all patients included a history and physical examination including a digital rectal exam, chest X-ray, and routine serum laboratory studies (complete blood count and biochemistry panel including alkaline phosphatase). The Tandem-R monoclonal method (Hybridtech Inc., San Diego, CA, USA) or the Abbott microparticle immunoassay (IMX, Abbott Laboratories, Chicago, IL, USA) was used to measure pretreatment serum PSA. All patients underwent a prostate biopsy obtained with transrectal ultrasound 
Radiation technique
The RT technique for the high-dose rate boost protocol at WBH, KUH, and CET has been previously reported. [17] [18] [19] [20] In brief, all patients received treatment with external beam radiation using megavoltage linear accelerators (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) . In all three institutions, the prostate gland was boosted using two interstitial brachytherapy procedures. For all 560 cases, a single 3.5 mm Ir 192 retractable source utilizing a microselectron high-dose rate after-loading system (Nucletron BV, The Netherlands) was used. Ultrasound or CT-based 3D-conformal optimization was performed for all HDR procedures before treatment. The mean biologic equivalent prostate dose for the three centers was X100 Gy. 21 Biochemical failure (BF) was assessed using the ASTRO definition. Local failure for the purpose of this study was defined as the appearance of a new nodular density on the prostate on physical examination. If clinically indicated, a transrectal ultrasound and pathologic confirmation was obtained. Distant metastasis (DM) was defined as definitive evidence of metastatic lesions on radiological examination; pathologic confirmation was required if clinical or radiological examination was equivocal. Clinical events included local failure and DM. BF was not counted as a clinical event. Diseasefree survival was calculated for all live patients and reflected all clinical events as just defined. Follow-up was defined as the interval from the finalization of RT to the last known patient contact and was used for all time calculations. Overall survival reflected all deaths, cancerrelated or otherwise. Cause-specific survival (CSS) was based upon deaths that could be attributed to prostate cancer. In those cases where the cause of death was unclear, the presence of clinically evident prostate cancer at the time of death was considered death owing to prostate cancer.
All of the 560 patients identified as eligible were used for analysis. A w 2 test was used to assess the independence of individual risk factors between the NAD group and the no NAD group in Table 1a and 1b. Different risk groups were matched using different GS, pretreatment PSA, or clinical T stage cutoffs. The estimated likelihood of events for these risk groups was calculated by the Kaplan-Meier method. 22 The statistical significance of differences between these curves was calculated with the log-rank test. Log-rank tests were used based on the observation that outcomes within a population change over time and are not fixed while treatment allocation is predetermined. A Cox proportional hazards model was used for univariate and multivariate analysis for DM and prostate cancer death. 23 A P-value of r0.05 was considered statistically significant. Times were censored from the date of finalization of all radiation treatments.
Statistical analysis was performed with SYSTAT version 10.0 (SPSS Inc., Chicago, IL, USA).
Results
For all 560 cases, median follow-up was 4 years with a mean of 4.4 years (range, 1.5-14.5 years). Five hundred thirty-eight patients have been followed for X5 years, 175 for X8 years, and 53 for X10 years. For all 560 cases, median age at diagnosis was 64 years, median RT dose was 42 Gy, and median HDR dose was 24 Gy. Three hundred and eight patients were treated with AD for a median time of 3 months. No significant difference was seen between the two treatment groups in terms of age, treatment doses, GS, clinical T stage, or pretreatment PSA (Table 1a and 1b).
Outcome data for all patients as well as outcomes broken down by different risk groups and by the use of AD are listed in Table 2 . For all 560 cases, a significant detrimental increase in DM (P ¼ 0.04, Figure 1a ) and prostate cancer mortality (P ¼ 0.02, Figure 1b) was seen with the use of NAD. As patients were further matched for analysis using specific cutoffs for various risk factors, we found a consistent detrimental effect in terms of DM and prostate cancer death for the higher GS group (8-10), palpable disease (XT2a), and a pretreatment PSA X15 ng/ml. A significant difference in DM and prostate cancer death continued to be seen when patients were selected by any one of these three risk factors (GS, T stage, or PSA) or when patients were selected by having both a high GS and palpable disease. Outcomes for patients who had all three risk factors (GS 8-10, palpable disease, and PSAX15) are also listed in Table 2 . In this subgroup of patients, NAD increased the risk of DM (P ¼ 0.007, Figure 2a ), cancer-specific mortality (P ¼ 0.01, Figure 2b ), and decreased overall survival (P ¼ 0.01, Figure 2c ). The absolute detrimental difference in DM rates with the use of NAD was 57%. For prostate cancerspecific death and overall death, the absolute detrimental difference was 31% with the use of NAD. All patients who died in this group died from their prostate cancer. No subgroup was identified among this high-risk population where NAD did not have a detrimental effect in clinical outcome. However, patients with a GS of 7 (n ¼ 244) had no significant difference with and without hormones at 5-year CSS (97 vs 99% (P ¼ 0.7)) and 5-year DM (7 vs 5% (P ¼ 0.4)). In addition, patients with a PSAX10 and o15 (n ¼ 115) also had no significant difference with and without hormones at 5-year CSS (98 vs 95% (P ¼ 0.3)) and 5-year DM (2 vs 5% (P ¼ 0.3)). This was also true for all patients with a GSp7 or a pretreatment PSAp15.
The results from a Cox proportional hazard univariate and multivariate analysis for DM can be seen in Table 3a and for cancer deaths in Table 3b . The difference in DM and prostate cancer death for the NAD versus the no AD group increased with higher GS, clinical T stage, and pretreatment PSA values (Tables 3a and 3b) .
Time intervals were also tested using Cox proportional univariate and multivariate analysis. The time between the start of AD and the first RT treatment was significant in univariate analysis (Po0.001) for any failure (BF, ASTRO, clinical failure, or salvage AD). This was also High-dose radiation and NAD C Vargas et al true for DM (P ¼ 0.001) and event-free survival ((P ¼ 0.001) patients alive and free of any failure). The longer the time interval between the two, the larger the detrimental effect on outcome. Furthermore, this finding remained significant for any failure (biochemical or clinical), DM, or event-free survival using Cox proportional multivariate analysis (P ¼ 0.005, P ¼ 0.045, Po0.001, respectively) when analyzed with the significant risk factors of the multivariate analysis (MVA) listed in Table 3a .
Clinical T stage (1992 AJCC), GS, pretreatment PSA, number of brachytherapy needles used, AD, HDR, and treating institution were significant risk factors for DM on univariate analyses. However, only GS (P ¼ 0.003, HR 2.8) and the use of NAD (P ¼ 0.03, HR 2.7) were independently significant on multivariate analysis.
The results from the Cox proportional hazard univariate and multivariate analyses for prostate cancer death are listed in Table 4 . Clinical T stage (1992 AJCC), GS, pretreatment PSA, number of brachytherapy needles used, AD, HDR, and treating institution were again significant risk factors for prostate cancer death on univariate analysis. Likewise, only GS (P ¼ 0.01, HR 3.3) and the use of NAD (P ¼ 0.04, HR 4.3) were independently significant on multivariate analysis.
Discussion
The need for NAD with high-dose RT is an unanswered question. AD (mainly concurrent and adjuvant) has been shown to improve clinical outcome in patients treated to low radiation doses (65-70 Gy) as demonstrated in Table 4 . Unfortunately, neoadjuvant hormonal therapy has not been found to improve outcomes and its prolonged use leads to a delay in RT.
Androgen deprivation and radiation therapy
As mentioned above, low-dose radiation and AD has been found to be beneficial (Table 4) . However, if AD has a synergistic effect with radiation, as suggested by the previously mentioned studies, higher radiation doses may decrease the absolute benefit of AD. Thus, initiating definitive RT early in the course of therapy may prove to decrease recurrence rates when compared to the same therapy later in the treatment. It is thought provoking that studies for lung cancer have shown a benefit for early radiation. [30] [31] [32] Other studies looking at the delivery of NAD include a phase III Canadian study by Crook et al., which reported no benefit for the addition of 3 or High-dose radiation and NAD C Vargas et al 8 months of neoadjuvant hormonal therapy. Hence, the question of whether neoadjuvant hormones will have a benefit on prostate cancer outcomes, particularly in high-risk patients treated with high-dose RT, remains unclear.
In our study, no benefit was seen with the addition of NAD for p6 months before definitive RT. The delay in RT for this high-risk population owing to hormonal therapy increased the probability of metastasis and subsequent death from prostate cancer. This was especially true as the GS and clinical T stage increased, or for patients with a higher pretreatment PSA value as seen in the Cox proportional hazard univariate analysis in Tables 3a and 3b . These results may be explained as patients with the most aggressive disease at presentation would be affected the most from a delay in RT. Thus, more aggressive disease would result in a higher risk of disease dissemination and cancer mortality.
A phase III study of NAD before surgery for T2b cancer patients was reported by Soloway et al. 33 No benefit was seen for the use of AD in terms of BF rates; however, for margin-negative prostate cancer BF rates were higher with than without NAD. As BF was still seen in negative margin cases, it is potentially possible that prostate cancer cells migrated outside the prostate before the surgical procedure.
Previous studies have also suggested a detrimental effect when curative therapy was delayed. Nguyen et al. 34 found a detrimental effect in biochemical control for high-risk patients treated with RT with a median delay 42.5 months. Nam et al. 35 also found a detrimental effect in biochemical control for surgically treated patients with a delay 43 months. Our data are consistent with the previously published studies that suggest that a delay in curative therapy could have a detrimental impact on outcome.
No apparent difference was seen in BF rates for patients treated with and without NAD. In patients with NAD, BF rates were closer to clinical failure rates than in High-dose radiation and NAD C Vargas et al patients without NAD for whom more BFs were seen than clinical events. If BF is considered a surrogate for clinical failure, NAD will decrease false positives rates but will bias the comparison for patients treated with and without NAD.
Potential sources of error
The AD group and the no AD group were well balanced with respect to GS, pretreatment PSA, and clinical T stage as shown in Table 1a and 1b. Regardless, it is possible that a selection bias favored the no AD patients. To decrease the confounding effect of a known risk factor in the analysis, patients were matched and analyzed in the different subgroups shown in Table 2 . The group with the most closely matched risk factors was the group with GS 8-10, clinical palpable disease, and pretreatment PSA 415 as these patients were matched for all three major risk factors. This group also showed the largest differences in clinical outcomes following the use of AD. MVA adjusting for different risk factors found NAD to be detrimental. An additional potential source of bias in this analysis is the fact that treatment was administered at different institutions. To asses any potential bias secondary to institutional treatment, Cox proportional hazard univariate and multivariate analyses were performed examining HDR dose, external beam RT dose, and institution as seen in Tables 3a and 3b . After accounting for known clinical (GS, PSA, T stage, and age) and the above treatment-related risk factors (prostate volume and number of needles), multivariate analysis demonstrated a detrimental effect associated with AD in terms of distant metastases and prostate cancer death. That is, curative therapy delay while using AD was independent of all major risk factors or differences in treatment. The time interval between the start of the NAD and the start of RT was also found to be significant in Cox univariate and multivariate analysis for different outcomes.
Several different explanations for the detrimental effect of NAD are also possible. We do not believe that the worse outcome seen with NAD could have been related to gland volume as the prostate volume before therapy was not found to be related to outcome and neither was the number of needles. It has been put forth that prostate cancer cells could have been left at the periphery of the prostate gland as it was down-sized with NAD. Although this theory is appealing, we do not believe that this would have led to a detrimental effect in outcome as the planning target volume was optimized by giving margins larger than 3 mm around the prostate. Furthermore, external radiation was also given. Lack of a central review could also have impacted the results. Retrospective analyses, like the one presented here, are thought provoking. However, well-performed randomized studies are necessary to further define the role of AD and its timing with high-dose radiation therapy especially when brachytherapy is used as in the present study.
Several potential explanations are finally possible. (1) Our results are due to bias not fully accounted for by the use of known risk factors. (2) Target definition uncertainty after NAD. (3) The beneficial effect of AD is mainly owing to a synergistic effect with radiation, in which case higher doses improving cancer cell eradication may decrease the absolute impact of AD. In the same way, high-dose RT may also be more effective earlier in the course of therapy.
Conclusions
No benefit was apparent for the use of NAD and highdose RT in our study. For the contrary high-dose RT and NAD was associated with metastasis independently of other known risk factors in different subgroup analyses and MVA. Based on our results, we favor the use of concurrent/adjuvant AD over prolonged NAD for prostate cancer patients for whom AD is clinically indicated. High-dose radiation and NAD C Vargas et al 
